EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis—this poses challenges for effective surgical control and future tumor-related...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/499 |
| _version_ | 1797434130351259648 |
|---|---|
| author | Balakarthikeyan Janani Mayakrishnan Vijayakumar Kannappan Priya Jin Hee Kim D. S. Prabakaran Mohammad Shahid Sameer Al-Ghamdi Mohammed Alsaidan Nasraddin Othman Bahakim Mohammad Hassan Abdelzaher Thiyagarajan Ramesh |
| author_facet | Balakarthikeyan Janani Mayakrishnan Vijayakumar Kannappan Priya Jin Hee Kim D. S. Prabakaran Mohammad Shahid Sameer Al-Ghamdi Mohammed Alsaidan Nasraddin Othman Bahakim Mohammad Hassan Abdelzaher Thiyagarajan Ramesh |
| author_sort | Balakarthikeyan Janani |
| collection | DOAJ |
| description | Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis—this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities. |
| first_indexed | 2024-03-09T10:27:49Z |
| format | Article |
| id | doaj.art-0c4ef609209941038c0b2b815e17dd65 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T10:27:49Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-0c4ef609209941038c0b2b815e17dd652023-12-01T21:30:14ZengMDPI AGVaccines2076-393X2022-03-0110449910.3390/vaccines10040499EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and ChallengesBalakarthikeyan Janani0Mayakrishnan Vijayakumar1Kannappan Priya2Jin Hee Kim3D. S. Prabakaran4Mohammad Shahid5Sameer Al-Ghamdi6Mohammed Alsaidan7Nasraddin Othman Bahakim8Mohammad Hassan Abdelzaher9Thiyagarajan Ramesh10Department of Biochemistry, PSG College of Arts and Science (Autonomous), Bharathiar University, Coimbatore 641014, Tamil Nadu, IndiaDepartment of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, 209 Neugdong-ro, Gwangjin-gu, Seoul 05006, KoreaDepartment of Biochemistry, PSG College of Arts and Science (Autonomous), Bharathiar University, Coimbatore 641014, Tamil Nadu, IndiaDepartment of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, 209 Neugdong-ro, Gwangjin-gu, Seoul 05006, KoreaDepartment of Radiation Oncology, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-gu, Cheongju 28644, KoreaDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaFamily and Community Medicine Department, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaInternal Medicine Department, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaColorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis—this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.https://www.mdpi.com/2076-393X/10/4/499colorectal cancerEGFRnanocarriersnanomedicinecetuximab |
| spellingShingle | Balakarthikeyan Janani Mayakrishnan Vijayakumar Kannappan Priya Jin Hee Kim D. S. Prabakaran Mohammad Shahid Sameer Al-Ghamdi Mohammed Alsaidan Nasraddin Othman Bahakim Mohammad Hassan Abdelzaher Thiyagarajan Ramesh EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges Vaccines colorectal cancer EGFR nanocarriers nanomedicine cetuximab |
| title | EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges |
| title_full | EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges |
| title_fullStr | EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges |
| title_full_unstemmed | EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges |
| title_short | EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges |
| title_sort | egfr based targeted therapy for colorectal cancer promises and challenges |
| topic | colorectal cancer EGFR nanocarriers nanomedicine cetuximab |
| url | https://www.mdpi.com/2076-393X/10/4/499 |
| work_keys_str_mv | AT balakarthikeyanjanani egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT mayakrishnanvijayakumar egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT kannappanpriya egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT jinheekim egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT dsprabakaran egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT mohammadshahid egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT sameeralghamdi egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT mohammedalsaidan egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT nasraddinothmanbahakim egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT mohammadhassanabdelzaher egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges AT thiyagarajanramesh egfrbasedtargetedtherapyforcolorectalcancerpromisesandchallenges |